Stock IdeasStrong Buy Stocks

Strong Buy Stocks from Top Wall Street Analysts

Latest stocks with a Strong Buy rating from the top performing 25% of analysts tracked by WallStreetZen

Canaccord Genuity's William Plovanic raised their price target on Dexcom (NASDAQ: DXCM) by 5.3% from $95 to $100 on 2026/05/02. The analyst maintained their Strong Buy rating on the stock.

Dexcom reported its Q1 2026 earnings.

In spite of somewhat better-than-expected revenue, Plovanic called the quarter's adjusted GM the most meaningful metric, delivering much higher adjusted OMs and adjusted EBITDA.

Plovanic said management increased its guidance solely to reflect Q1's results.

Earnings Report

For Q1 2026, Dexcom reported:

• EPS of $0.56, which beat the Zacks Consensus Estimate of $0.47 and, by 75%, Q1 2025’s $0.32.
• Revenue of $1.19B, which beat the Zacks Consensus Estimate by 1.31% and, by 15%, Q1 2025’s $1.04B.

For FY 2026, management guided:

• Revenue of $5.16B to $5.25B.

President & CEO Jake Leach commented: Dexcom delivered strong revenue growth and margin performance to start the year, reflecting healthy demand for Dexcom CGM and continued operational improvement.

“We will work to build on this momentum throughout 2026 and look forward to highlighting Dexcom’s long-term growth opportunity at our Investor Day in the coming weeks.”